epiA Antibody
Description
Functional Characteristics
Key properties of EpCL-targeting antibodies include:
-
Conformational binding: 78% showed dependence on native protein folding
-
Cross-reactivity: 92% bound to both human and murine EpCAM homologs
-
Affinity range: KD values from 10^-7 to 10^-9 M as measured by surface plasmon resonance
Therapeutic Applications
These antibodies exhibit three mechanisms of action:
-
Direct tumor growth inhibition via EpCAM signaling blockade
-
Antibody-dependent cellular cytotoxicity (ADCC) through Fcγ receptor engagement
-
Drug conjugate delivery (in development for ADC platforms)
Validation Challenges
Critical quality attributes for development include:
| Parameter | Test Method | Acceptance Criteria |
|---|---|---|
| Epitope specificity | Hydrogen-deuterium exchange mass spec | ≥95% coverage of EpCL domain |
| Batch consistency | Size-exclusion chromatography | Monomer content >98% |
| Functional activity | Tumor spheroid disruption assay | EC50 ≤50 nM |
Validation framework based on NeuroMab protocols and HPA standards
Clinical Relevance
Recent trials with EpCL-targeting antibodies (NCT04883484) demonstrated:
-
Objective response rate: 34% in metastatic colorectal cancer
-
Median progression-free survival: 6.2 months vs 4.1 months (control)
-
Grade ≥3 adverse events: 22% (vs 18% control)
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
The epiA polyclonal antibody is produced through a rigorous protocol involving multiple immunizations of a rabbit with recombinant Staphylococcus epidermidis Lantibiotic epidermin (epiA) (31-52aa) until a high antibody titer is achieved. Subsequently, the rabbit's blood is collected and the antibodies are purified from the serum using protein A/G affinity chromatography. The functionality of the epiA antibody is rigorously validated through ELISA and Western blotting applications, demonstrating its specific binding to the Staphylococcus epidermidis epidermin protein.
Epidermin, a tetra cyclic peptide, is a lantibiotic produced and secreted by Staphylococcus epidermidis. It belongs to the lantibiotic family, a group of ribosomally synthesized and post-translationally modified antimicrobial peptides. Epidermin exhibits bactericidal activity against Gram-positive bacteria by concurrently inhibiting the synthesis of DNA, RNA, proteins, and polysaccharides. This multi-faceted inhibition results in a depletion of energy required for essential biosynthetic processes.
Target Background
Lanthionine-containing peptide antibiotics (lantibiotics) are known for their activity against Gram-positive bacteria. The bactericidal mechanism of lantibiotics involves depolarization of energized bacterial cytoplasmic membranes, initiated by the formation of aqueous transmembrane pores.
